SB-258,719
Encyclopedia
SB-258,719 is a drug developed by GlaxoSmithKline
which acts as a selective 5-HT7 receptor
partial inverse agonist
, and was the first such ligand identified for 5-HT7. Its use in research has mainly been in demonstrating the potential use for 5-HT7 agonists as potential novel analgesic
s, due to the ability of SB-258,719 to block the analgesic effects of a variety of 5-HT7 agonists across several different testing models.
GlaxoSmithKline
GlaxoSmithKline plc is a global pharmaceutical, biologics, vaccines and consumer healthcare company headquartered in London, United Kingdom...
which acts as a selective 5-HT7 receptor
Receptor (biochemistry)
In biochemistry, a receptor is a molecule found on the surface of a cell, which receives specific chemical signals from neighbouring cells or the wider environment within an organism...
partial inverse agonist
Inverse agonist
In the field of pharmacology, an inverse agonist is an agent that binds to the same receptor as an agonist but induces a pharmacological response opposite to that agonist....
, and was the first such ligand identified for 5-HT7. Its use in research has mainly been in demonstrating the potential use for 5-HT7 agonists as potential novel analgesic
Analgesic
An analgesic is any member of the group of drugs used to relieve pain . The word analgesic derives from Greek an- and algos ....
s, due to the ability of SB-258,719 to block the analgesic effects of a variety of 5-HT7 agonists across several different testing models.